Annexon (ANNX) Operating Income (2019 - 2026)
Annexon (ANNX) posted quarterly Operating Income of -$46.1 million for Q1 2026, up 19.78% year-over-year from -$38.4 million in Q1 2025, and up 8.37% quarter-over-quarter from -$50.3 million in Q4 2025.
Analysis
Annexon (ANNX) Operating Income (2019 - 2026) Analysis & Trends
Annexon's Operating Income history runs 8 years deep, the most recent figure standing at -$46.1 million for Q1 2026.
- In Q1 2026, Operating Income rose 19.78% year-over-year to -$46.1 million; the TTM figure through Mar 2026 stood at -$205.1 million (down 12.11% YoY), while the FY2025 annual figure was -$216.4 million, down 40.46% from the prior year.
- Operating Income for Q1 2026 stood at -$46.1 million, up from -$50.3 million in the prior quarter.
- The five-year high for Operating Income was -$28.6 million in Q1 2024, with the low at -$57.4 million in Q1 2025.
- The 5-year median for Operating Income is -$37.7 million (2023), against an average of -$41.5 million.
- The sharpest annual moves came in 2024 and 2025: Operating Income soared 30.72% in 2024, then tumbled 100.91% in 2025.
- Annexon's Operating Income stood at -$36.7 million in 2022, then increased by 18.22% to -$30.0 million in 2023, then plunged by 74.88% to -$52.5 million in 2024, then advanced by 4.23% to -$50.3 million in 2025, then climbed by 8.37% to -$46.1 million in 2026.
- Business Quant data shows ANNX's Operating Income at -$46.1 million in Q1 2026, -$50.3 million in Q4 2025, and -$57.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Annexon | 978.89 Mn | 978.89 Mn | - | -57.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -57.23 Mn |
| Mar 31, 2026 | -46.05 Mn |
| Dec 31, 2025 | -50.26 Mn |
| Sep 30, 2025 | -57.02 Mn |
| Jun 30, 2025 | -51.73 Mn |
| Mar 31, 2025 | -57.41 Mn |
| Dec 31, 2024 | -52.48 Mn |
| Sep 30, 2024 | -39.44 Mn |
| Jun 30, 2024 | -33.58 Mn |
| Mar 31, 2024 | -28.57 Mn |
| Dec 31, 2023 | -30.01 Mn |
| Sep 30, 2023 | -34.78 Mn |
| Jun 30, 2023 | -37.69 Mn |
| Mar 31, 2023 | -41.24 Mn |
| Dec 31, 2022 | -36.70 Mn |
| Sep 30, 2022 | -36.07 Mn |
| Jun 30, 2022 | -37.41 Mn |
| Mar 31, 2022 | -35.43 Mn |
| Dec 31, 2021 | -37.46 Mn |
| Sep 30, 2021 | -35.68 Mn |